Literature DB >> 8664140

A prospective study of urinary oestrogen excretion and breast cancer risk.

T J Key1, D Y Wang, J B Brown, C Hermon, D S Allen, J W Moore, R D Bulbrook, I S Fentiman, M C Pike.   

Abstract

To test the hypothesis that high levels of endogenous oestrogens increase the risk for developing breast cancer, concentrations of oestrone, oestradiol and oestriol were measured in 24 h urine samples from 1000 women participants in a prospective study of breast cancer on the island of Guernsey. Sixty-nine subjects were diagnosed with breast cancer subsequent to urine collection. Among women who were premenopausal at the time of urine collection, cases excreted less oestrogen than controls; the odds ratios (95% CI) for breast cancer in the middle and upper thirds of the distribution of oestrogen excretion, in comparison with the lower third (reference group, assigned odds ratio = 1.0), were 0.5(0.2-1.2) and 0.4(0.2-1.1) respectively for oestrone, 0.8(0.4-1.8 and 0.4(0.2-1.1) for oestradiol, 0.7(0.3-1.6) and 0.7(0.3-1.6) for oestriol and 0.9(0.4-2.0) and 0.5(0.2-1.3) for total oestrogens. Among women who were post-menopausal at the time of urine collection, the trend was in the opposite direction, with an increase in risk associated with increased oestrogen excretion; the odds ratios were 0.9(0.3-2.2) and 1.1(0.5-2.8) for oestrone, 0.8(0.3-2.3) and 1.9(0.8-4.6) for oestradiol, 1.5(0.6-3.9) and 1.8(0.7-4.6) for oestriol and 0.9(0.4-2.6) and 1.9(0.7-4.7) for total oestrogens. The trends of increasing risk with increasing oestrogen excretion among post-menopausal women were statistically significant for oestradiol (P = 0.022) and for total oestrogens (P = 0.016). We conclude that high levels of endogenous oestrogens in post-menopausal women are associated with increased breast cancer risk, but that the relationship of oestrogens in premenopausal women with risk is unclear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664140      PMCID: PMC2074556          DOI: 10.1038/bjc.1996.304

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  II. URINARY EXCRETION OF ESTRONE, ESTRADIOL, AND ESTRIOL BY PATIENTS WITH BREAST CANCER AND BENIGN BREAST DISEASE.

Authors:  J MARMORSTON; L G CROWLEY; S M MYERS; E STERN; C E HOPKINS
Journal:  Am J Obstet Gynecol       Date:  1965-06-15       Impact factor: 8.661

2.  Endocrine profiles and breast cancer.

Authors:  A E Argüelles; U L Poggi; C Saborida; C Hoffman; M Chekherdemian; O Blanchard
Journal:  Lancet       Date:  1973-01-27       Impact factor: 79.321

3.  Plasma hormones in pre- and postmenopausal breast cancer.

Authors:  D Drafta; A E Schindler; S M Milcu; E Keller; E Stroe; E Horodniceanu; I Bălănescu
Journal:  J Steroid Biochem       Date:  1980-07       Impact factor: 4.292

4.  Origin of serum estradiol in postmenopausal women.

Authors:  H L Judd; I M Shamonki; A M Frumar; L D Lagasse
Journal:  Obstet Gynecol       Date:  1982-06       Impact factor: 7.661

5.  Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease.

Authors:  W B Malarkey; L L Schroeder; V C Stevens; A G James; R R Lanese
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

6.  Hormonal regulation of the menstrual cycle in women with breast cancer: effect of adjuvant chemotherapy.

Authors:  B M Sherman; R B Wallace; P R Jochimsen
Journal:  Clin Endocrinol (Oxf)       Date:  1979-03       Impact factor: 3.478

7.  Urine estrogens, frequency of ovulation, and breast cancer risk: case-control study in premenopausal women.

Authors:  B MacMahon; P Cole; J B Brown; R Paffenbarger; D Trichopoulos; S Yen
Journal:  J Natl Cancer Inst       Date:  1983-02       Impact factor: 13.506

8.  Estrogen profiles of premenopausal women with breast cancer.

Authors:  P Cole; D Cramer; S Yen; R Paffenbarger; B MacMahon; J Brown
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

9.  Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls.

Authors:  J W Moore; G M Clark; R D Bulbrook; J L Hayward; J T Murai; G L Hammond; P K Siiteri
Journal:  Int J Cancer       Date:  1982-01-15       Impact factor: 7.396

10.  Serum oestradiol-17 beta in women with benign and malignant breast disease.

Authors:  P C England; L G Skinner; K M Cottrell; R A Sellwood
Journal:  Br J Cancer       Date:  1974-12       Impact factor: 7.640

View more
  20 in total

1.  High-throughput sample preparation and analysis using 96-well membrane solid-phase extraction and liquid chromatography-tandem mass spectrometry for the determination of steroids in human urine.

Authors:  G Rule; J Henion
Journal:  J Am Soc Mass Spectrom       Date:  1999-12       Impact factor: 3.109

2.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

3.  Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk.

Authors:  Susan E Hankinson; A Heather Eliassen
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

Review 4.  A new approach to measuring estrogen exposure and metabolism in epidemiologic studies.

Authors:  R G Ziegler; J M Faupel-Badger; L Y Sue; B J Fuhrman; R T Falk; J Boyd-Morin; M K Henderson; R N Hoover; T D Veenstra; L K Keefer; X Xu
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-09       Impact factor: 4.292

5.  Stability of 15 estrogens and estrogen metabolites in urine samples under processing and storage conditions typically used in epidemiologic studies.

Authors:  Barbara J Fuhrman; Xia Xu; Roni T Falk; Susan E Hankinson; Timothy D Veenstra; Larry K Keefer; Regina G Ziegler
Journal:  Int J Biol Markers       Date:  2010 Oct-Dec       Impact factor: 2.659

Review 6.  Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.

Authors:  Swann Arp Adams; James R Hebert; Susan Bolick-Aldrich; Virginie G Daguise; Catishia M Mosley; Mary V Modayil; Sondra H Berger; Jane Teas; Michael Mitas; Joan E Cunningham; Susan E Steck; James Burch; William M Butler; Marie-Josephe D Horner; Heather M Brandt
Journal:  J S C Med Assoc       Date:  2006-08

7.  Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women.

Authors:  Steven C Moore; Charles E Matthews; Xiao Ou Shu; Kai Yu; Mitchell H Gail; Xia Xu; Bu-Tian Ji; Wong-Ho Chow; Qiuyin Cai; Honglan Li; Gong Yang; David Ruggieri; Jennifer Boyd-Morin; Nathaniel Rothman; Robert N Hoover; Yu-Tang Gao; Wei Zheng; Regina G Ziegler
Journal:  J Natl Cancer Inst       Date:  2016-05-18       Impact factor: 13.506

8.  Intestinal oleoyl-estrone esterase activity in the Wistar rat.

Authors:  M Serrano-Muñoz; M M Grasa; D González-Martínez; C Cabot; J A Fernández-López; M Alemany
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

9.  A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability.

Authors:  Roni T Falk; Xia Xu; Larry Keefer; Timothy D Veenstra; Regina G Ziegler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

10.  Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer.

Authors:  N C Onland-Moret; R Kaaks; P A H van Noord; S Rinaldi; T Key; D E Grobbee; P H M Peeters
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.